Clinicopathological characteristics of the patients in the training set according to BCL2 IHC scores
| . | . | BCL2 IHC score . | . | . | ||
|---|---|---|---|---|---|---|
| . | Total . | 3+ . | 2+ . | 0 or 1+ . | P . | |
| Characteristics . | n = 218 (%) . | n = 89 (%) . | n = 55 (%) . | n = 74 (%) . | 3+ vs 2+ . | 3+ vs 0 to 2+ . |
| Age >60 y | 146 (67) | 60 (68) | 39 (70) | 47 (64) | .66 | .91 |
| Sex, male | 114 (52) | 54 (51) | 27 (49) | 42 (57) | .86 | .67 |
| LDH > normal | 112 (51) | 55 (62) | 26 (47) | 31 (42) | .09 | .01 |
| B symptoms+ | 40 (18) | 19 (22) | 11 (20) | 10 (14) | .85 | .34 |
| Hemoglobin < normal | 53 (24) | 23 (26) | 12 (22) | 18 (24) | .58 | .66 |
| Stage 3-4 | 83 (38) | 42 (47) | 21 (38) | 21 (28) | .29 | .03 |
| IPI 3-5 | 61 (28) | 32 (36) | 15 (27) | 15 (20) | .28 | .04 |
| Bone marrow involvement+ | 9 (4) | 6 (7) | 1 (2) | 2 (3) | .35 | .21 |
| Overall CNS involvement+ | 15 (7) | 9 (10) | 4 (7) | 1 (1) | .78 | .05 |
| Tumor size ≥7.5 cm | 60 (28) | 27 (30) | 11 (20) | 22 (30) | .17 | .44 |
| EBV-positive | 5 (2) | 0 (0) | 3 (5) | 2 (3) | ND | ND |
| CR | 187 (86) | 68 (76) | 49 (89) | 70 (95) | .06 | <.001* |
| Relapse after CR | 38/187 (20) | 28/68 (41) | 8/49 (16) | 2/70 (3) | .004 | <.001* |
| 3-y PFS rate (%) | 72 | 52 | 74 | 93 | .006 | <.001* |
| Non-GC type | 100 (46) | 52 (58) | 33 (60) | 15 (20) | .85 | .002* |
| CD10+ | 92 (42) | 28 (31) | 17 (31) | 47 (64) | .94 | .008 |
| MYC IHC > 60% | 24 (11) | 12 (14) | 5 (9) | 7 (9) | .43 | .33 |
| MYC IHC ≥ 40% | 86 (40) | 40 (43) | 21 (38) | 25 (34) | .42 | .49 |
| MYC rearrangement+ | 30 (14) | 22 (25) | 2 (4) | 6 (8) | <.001* | <.001* |
| BCL2 rearrangement+ | 20 (9) | 15 (17) | 2 (4) | 3 (4) | .02 | <.001* |
| BCL6 rearrangement+ | 46 (21) | 22 (25) | 14 (25) | 10 (14) | .92 | .27 |
| MYC and BCL2 and/or BCL6 rearrangements+ | 15 (7) | 13 (15) | 1 (2) | 1 (1) | .01 | <.001* |
| . | . | BCL2 IHC score . | . | . | ||
|---|---|---|---|---|---|---|
| . | Total . | 3+ . | 2+ . | 0 or 1+ . | P . | |
| Characteristics . | n = 218 (%) . | n = 89 (%) . | n = 55 (%) . | n = 74 (%) . | 3+ vs 2+ . | 3+ vs 0 to 2+ . |
| Age >60 y | 146 (67) | 60 (68) | 39 (70) | 47 (64) | .66 | .91 |
| Sex, male | 114 (52) | 54 (51) | 27 (49) | 42 (57) | .86 | .67 |
| LDH > normal | 112 (51) | 55 (62) | 26 (47) | 31 (42) | .09 | .01 |
| B symptoms+ | 40 (18) | 19 (22) | 11 (20) | 10 (14) | .85 | .34 |
| Hemoglobin < normal | 53 (24) | 23 (26) | 12 (22) | 18 (24) | .58 | .66 |
| Stage 3-4 | 83 (38) | 42 (47) | 21 (38) | 21 (28) | .29 | .03 |
| IPI 3-5 | 61 (28) | 32 (36) | 15 (27) | 15 (20) | .28 | .04 |
| Bone marrow involvement+ | 9 (4) | 6 (7) | 1 (2) | 2 (3) | .35 | .21 |
| Overall CNS involvement+ | 15 (7) | 9 (10) | 4 (7) | 1 (1) | .78 | .05 |
| Tumor size ≥7.5 cm | 60 (28) | 27 (30) | 11 (20) | 22 (30) | .17 | .44 |
| EBV-positive | 5 (2) | 0 (0) | 3 (5) | 2 (3) | ND | ND |
| CR | 187 (86) | 68 (76) | 49 (89) | 70 (95) | .06 | <.001* |
| Relapse after CR | 38/187 (20) | 28/68 (41) | 8/49 (16) | 2/70 (3) | .004 | <.001* |
| 3-y PFS rate (%) | 72 | 52 | 74 | 93 | .006 | <.001* |
| Non-GC type | 100 (46) | 52 (58) | 33 (60) | 15 (20) | .85 | .002* |
| CD10+ | 92 (42) | 28 (31) | 17 (31) | 47 (64) | .94 | .008 |
| MYC IHC > 60% | 24 (11) | 12 (14) | 5 (9) | 7 (9) | .43 | .33 |
| MYC IHC ≥ 40% | 86 (40) | 40 (43) | 21 (38) | 25 (34) | .42 | .49 |
| MYC rearrangement+ | 30 (14) | 22 (25) | 2 (4) | 6 (8) | <.001* | <.001* |
| BCL2 rearrangement+ | 20 (9) | 15 (17) | 2 (4) | 3 (4) | .02 | <.001* |
| BCL6 rearrangement+ | 46 (21) | 22 (25) | 14 (25) | 10 (14) | .92 | .27 |
| MYC and BCL2 and/or BCL6 rearrangements+ | 15 (7) | 13 (15) | 1 (2) | 1 (1) | .01 | <.001* |
CNS, central nervous system; LDH, lactate dehydrogenase; ND, not determined.
P values significant after adjusted for multiple comparisons using Bonferroni correction, α = 0.05/21 = 0.0024.